OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

On the Horizon in NSCLC: Antibody Drug Conjugates

home / news-network / on-the-horizon-in-nsclc-antibody-drug-conjugates

Experts discuss current and investigational antibody drug conjugates (ADCs) in non-small cell lung cancer treatment and how they affect therapy approaches.

Advertisement
ADC Technology and Mechanism of Action

EP. 1: ADC Technology and Mechanism of Action

By Edward S. Kim, MD, MBA
Alexander Spira, MD, PhD, FACP
July 13th 2022

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

ADCs in Non-Small Cell Lung Cancer

EP. 2: ADCs in Non-Small Cell Lung Cancer

By Edward S. Kim, MD, MBA
Alexander Spira, MD, PhD, FACP
July 21st 2022

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

The Impact of ADCs on Non-Small Cell Lung Cancer Treatment

EP. 3: The Impact of ADCs on Non-Small Cell Lung Cancer Treatment

By Edward S. Kim, MD, MBA
Alexander Spira, MD, PhD, FACP
August 2nd 2022

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

ADCs in NSCLC: Audience Q&A

EP. 4: ADCs in NSCLC: Audience Q&A

By Edward S. Kim, MD, MBA
Alexander Spira, MD, PhD, FACP
August 8th 2022

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.

Latest Conference Coverage

Immunotherapy Monotherapy Leads to Antigen Loss and Treatment Resistance in Myeloma

PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma

At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact